Back to today’s briefing

Story perspectives

CergenX's Wave Device Receives FDA Breakthrough Designation

1/20/2025

42 10

Summary

Story summary

CergenX, an innovative Irish neurotech firm, has earned FDA Breakthrough Device Designation for its groundbreaking Wave device, which revolutionizes neonatal brain monitoring. Utilizing advanced AI for precise EEG assessments, it promises to detect brain injuries early. Additionally, CergenX's participation in the FDA's Total Product Lifecycle Advisory Program aims to accelerate the journey of transformative medical devices to those in need.

1 of 1

Story summary

CergenX, an innovative Irish neurotech firm, has earned FDA Breakthrough Device Designation for its groundbreaking Wave device, which revolutionizes neonatal brain monitoring. Utilizing advanced AI for precise EEG assessments, it promises to detect brain injuries early. Additionally, CergenX's participation in the FDA's Total Product Lifecycle Advisory Program aims to accelerate the journey of transformative medical devices to those in need.